Jon Resar, MD
Interventional Cardiology · Baltimore, MDNPI 1508808593
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (32.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Medtronic at 57.1% of the total. Reporting peaked in 2019 at $18,487 and has fallen 96.8% since, to $584 in 2025.
Across 197 payments — averaging $200.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$23K
- Boston Scientific$11K
- Haemonetics Corporation$3K
- Edwards Lifesciences$2K
- Abbott$926
- Recor Medical Inc$59
- plus $30 from 1 others
Across 179 payments — averaging $3085.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$393K
- Edwards Lifesciences$99K
- Abbott$61K
What the payments were for
- Consulting fees$12,81332%
- Speaking & faculty fees$9,90625%
- Travel & lodging$11,09928%
- Food & beverage$5,72314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 136 | $22,572 |
| Boston Scientific | 14 | $11,382 |
| Haemonetics Corporation | 1 | $3,000 |
| Edwards Lifesciences | 8 | $1,572 |
| Abbott | 36 | $926 |
| Recor Medical Inc | 1 | $59 |
| Abiomed | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,541 in reported general payments places this provider in the 85th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $20,386 |
| JardianceEmpagliflozin | 24 | $19,307 |
| Atorvastatin Calcium | 20 | $568 |
| Metoprolol Succinate | 21 | $322 |
| Losartan Potassium | 22 | $258 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Baltimore
- Aloke FinnBaltimore$575K
- John WangBaltimore$138K
- Diljon ChahalBaltimore$78K
- Faisal RahmanBaltimore$36K
- Matthew VossBaltimore$33K
- Hooman BakhshiBaltimore$32K
- Daniel AmbinderBaltimore$32K
- Rani HasanBaltimore$22K
- Ajar KocharBaltimore$22K
- Hani AlkhatibBaltimore$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.